Salama_edit.qxp 8/2/08 11:22 Page 65
Targeting B Cells with Rituximab – A Novel Therapy for Renal Disease and Transplantation
open-label pilot trial, Am J Respir Crit Care Med, study, J Am Soc Nephrol, 2003;14:1851–7. responders to undergo ABO-incompatible kidney
2006;173:180–87. 29. Cobo M, Hernandez D, Rodriguez C, Perez-Tamajon L, transplantation, Clin Transplant, 2004;18:254–60.
6. Pijpe J, van Imhoff GW, Spijkervet FK, et al., Rituximab Successful therapeutic use of rituximab in refractory 52. Sidner RA, Book BK, Agarwal A, et al., In vivo human B-cell
treatment in patients with primary Sjogren’s syndrome: an membranous glomerulonephritis, Clin Nephrol, 2006;66:54–7. subset recovery after in vivo depletion with rituximab, anti-
open-label phase II study, Arthritis Rheum, 2005;52:2740–50. 30. Jacobson SH, van Vollenhoven R, Gunnarsson I, Rituximab- human CD20 monoclonal antibody, Hum Antibodies,
7. Sfikakis PP, Boleti JN, Lionaki S, et al., Remission of induced long-term remission of membranous lupus nephritis, 2004;13:55–62.
proliferative lupus nephritis following B-cell depletion therapy is Nephrol Dial Transplant, 2006;21:1742–3. 53. Sonnenday CJ, Warren DS, Cooper M, et al., Plasmapheresis,
preceded by down-regulation of the T-cell costimulatory 31. Ratanatharathorn V, Ayash L, Reynolds C, et al., Treatment of CMV hyperimmune globulin and anti-CD20 allow ABO-
molecule CD40 ligand: an open-label trial, Arthritis Rheum, chronic graft-versus-host disease with anti-CD20 chimeric incompatible renal transplantation without splenectomy, Am J
2005;52:501–13. monoclonal antibody, Biol Blood Marrow Transplant, Transplant, 2004;4:1315–22.
8. Vallerskog T, Gunnarsson I, Widhe M, et al., Treatment with 2003;9:505–11. 54. Tyden G, Kumlien G, Genberg H, et al., ABO-Incompatible
rituximab affects both the cellular and the humoral arm of the 32. Gallon L, Chhabra D, Anti-CD20 monoclonal antibody Kidney Transplantations Without Splenectomy, Using Antigen-
immune system in patients with SLE, Clin Immunol, (rituximab) for the treatment of recurrent idiopathic Specific Immunoadsorption and Rituximab, Am J Transplant,
2007;122:62–74. membranous nephropathy in a renal transplant patient, Am J 20055:145–8.
9. Heller F, Lindenmeyer MT, Cohen CD, et al., The contribution of Transplant, 2006;6:3017–21. 55. Vieira CA, Agarwal A, Book BK, et al., Rituximab for reduction
B-cells to renal interstitial inflammation, Am J Pathol, 33. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D, Anti-CD20 of anti-HLA antibodies in patients awaiting renal
2007;170:457–68. monoclonal antibody (rituximab) treatment for hepatitis C- transplantation: 1. Safety, pharmacodynamics, and
10. Cohen CD, Calvaresi N, Armelloni S, et al., CD20-positive negative therapy-resistant essential mixed cryoglobulinemia pharmacokinetics, Transplantation, 2004;77:542–8.
infiltrates in human membranous glomerulonephritis, J Nephrol, with renal and cardiac failure, Am J Kidney Dis, 2004;43:e34–8. 56. Alausa M, Almagro U, Siddiqi N, et al., Refractory acute kidney
2005;18:328–33. 34. Ghobrial IM, Uslan DZ, Call TG, et al., Initial increase in the transplant rejection with CD20 graft infiltrates and successful
11. Kayler LK, Lakkis FG, Morgan C, et al., Acute cellular rejection cryoglobulin level after rituximab therapy for type II therapy with rituximab, Clin Transplant, 2005;19:137–40.
with CD20-positive lymphoid clusters in kidney transplant cryoglobulinemia secondary to Waldenstrom macroglobulinemia 57. Becker YT, Becker BN, Pirsch JD, Sollinger HW, Rituximab as
patients following lymphocyte depletion, Am J Transplant, does not indicate failure of response, Am J Hematol, treatment for refractory kidney transplant rejection, Am J
2007;7:949–54. 2004;77:329–30. Transplant, 2004;4:996–1001.
12. Martins HL, Silva C, Martini D, et al., Detection of B 35. Lamprecht P, Lerin-Lozano C, Merz H, et al., Rituximab induces 58. Samaniego M, Zachary A, Lucas D, et al., Early allograft
lymphocytes (CD20+) in renal allograft biopsy specimens, remission in refractory HCV-associated cryoglobulinaemic outcomes in patients with antibody mediated rejection treated
Transplant Proc, 2007;39:432–4. vasculitis, Ann Rheum Dis, 2003;62:1230–3. with rituximab: A single centre experience, Am J Transplant,
13. Edelbauer M, Jungraithmayr T, Zimmerhackl LB, Rituximab in 36. Roccatello D, Baldovino S, Rossi D, et al., Long-term effects of 2002;2(Suppl. 3):259A.
childhood systemic lupus erythematosus refractory to anti-CD20 monoclonal antibody treatment of cryoglobulinaemic 59. Choquet S, Leblond V, Herbrecht R, et al., Efficacy and safety of
conventional immunosuppression: case report, Pediatr Nephrol, glomerulonephritis, Nephrol Dial Transplant, 2004;19:3054–61. rituximab in B-cell post-transplant lymphoproliferative disorders:
2005;20:811–13. 37. Zaja F, De Vita S, Mazzaro C, et al., Efficacy and safety of results of a prospective multicentre phase II study, Blood, 2005.
14. Gottenberg J, Guillevin L, Lambotte O, et al., Tolerance and rituximab in type II mixed cryoglobulinemia, Blood, 60. Jain AB, Marcos A, Pokharna R, et al., Rituximab (Chimeric
short-term efficacy of rituximab in 43 patients with systemic 2003;101:3827–34. Anti-CD20 Antibody) for Posttransplant Lymphoproliferative
autoimmune diseases, Ann Rheum Dis, 2004. 38. Benz K, Dotsch J, Rascher W, Stachel D, Change of the course Disorder after Solid Organ Transplantation in Adults: Long-term
15. Leandro MJ, Edwards JC, Cambridge G, et al., An open study of of steroid-dependent nephrotic syndrome after rituximab Experience from a Single Centre, Transplantation,
B lymphocyte depletion in systemic lupus erythematosus, therapy, Pediatr Nephrol, 2004;19:794–7. 2005;80:1692–8.
Arthritis Rheum, 2002;46:2673–7. 39. Francois H, Daugas E, Bensman A, Ronco P, Unexpected 61. Oertel SH, Verschuuren E, Reinke P, et al., Effect of anti-CD 20
16. Marks SD, Patey S, Brogan PA, et al., B lymphocyte depletion efficacy of rituximab in multirelapsing minimal change nephrotic antibody rituximab in patients with post-transplant
therapy in children with refractory systemic lupus syndrome in the adults: first case report and pathophysiological lymphoproliferative disorder (PTLD), Am J Transplant,
erythematosus, Arthritis Rheum, 2005;52:3168–74. considerations, Am J Kidney Dis, 200749:158–61. 2005;5:2901–6.
17. Smith KGC, Burns S, Jayne DRW, A prospective trial of B-cell 40. Gossmann J, Scheuermann EH, Porubsky S, et al., Abrogation of 62. Rossi P, Demoux AL, Granel B, et al., Anti-CD20 monoclonal
depletion with Rituximab in refractory SLE, JASN, nephrotic proteinuria by rituximab treatment in a renal antibody for the treatment of refractory autoimmune haemolytic
2004;15:113A. transplant patient with relapsed focal segmental anaemia associated with idiopathic membranous nephropathy,
18. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al., glomerulosclerosis, Transpl Int, 2007. Rheumatology, 2005; 44:403–5.
Biopsy-verified response of severe lupus nephritis to treatment 41. Kamar N, Faguer S, Esposito L, et al., Treatment of focal 63. Gillis JZ, Dall’era M, Gross A, et al., Six refractory lupus patients
with rituximab (anti-CD20 monoclonal antibody) plus segmental glomerular sclerosis with rituximab: 2 case reports, treated with rituximab: a case series, Arthritis Rheum,
cyclophosphamide after biopsy-documented failure to respond Clin Nephrol, 2007;67:250–54. 2007;57:538–42.
to cyclophosphamide alone, Scand J Rheumatol, 42. Chemnitz J, Draube A, Scheid C, et al., Successful treatment of 64. Hristea D, Hadaya K, Marangon N, et al., Successful treatment
2004;33:423–7. severe thrombotic thrombocytopenic purpura with the of recurrent focal segmental glomerulosclerosis after kidney
19. Aries PM, Hellmich B, Both M, et al., Lack of efficacy of monoclonal antibody rituximab, Am J Hematol, 2002;71:105–8. transplantation by plasmapheresis and rituximab, Transpl Int,
Rituximab in Wegener’s Granulomatosis with refractory 43. Fakhouri F, Vernant JP, Veyradier A, et al., Efficiency of curative 2007;20:102–5.
granulomatous manifestations, Ann Rheum Dis, 2005. and prophylactic treatment with rituximab in ADAMTS13 65. Pescovitz MD, Book BK, Sidner RA, Resolution of recurrent focal
20. Eriksson P, Nine patients with anti-neutrophil cytoplasmic deficient-thrombotic thrombocytopenic purpura: a study of 11 segmental glomerulosclerosis proteinuria after rituximab
antibody-positive vasculitis successfully treated with rituximab, J cases, Blood, 2005. treatment, N Engl J Med, 2006;354:1961–3.
Intern Med, 2005;257:540–48. 44. Reddy PS, Deauna-Limayo D, Cook JD, et al., Rituximab in the 66. Faguer S, Kamar N, Guilbeaud-Frugier C, et al., Rituximab
21. Ferraro AJ, Day CJ, Drayson MT, Savage CO, Effective treatment of relapsed thrombotic thrombocytopenic purpura, therapy for acute humoral rejection after kidney transplantation,
therapeutic use of rituximab in refractory Wegener’s Ann Hematol, 2005;84:232–5. Transplantation, 2007;83:1277–80.
granulomatosis, Nephrol Dial Transplant, 2005;20:622–5. 45. Stein GY, Zeidman A, Fradin Z, et al., Treatment of resistant 67. Al-Akash SI, Al Makadma AS, Al Omari MG, Rapid response to
22. Kallenbach M, Dua H, Ring T, Rituximab induced remission in a thrombotic thrombocytopenic purpura with rituximab and rituximab in a pediatric liver transplant recipient with post-
patient with Wegener’s granulomatosis, Nephron Clin Pract, cyclophosphamide, Int J Hematol, 2004;80:94–6. transplant lymphoproliferative disease and maintenance with
2005;99:c92–6. 46. Yassa S, Blessios G, Marinides G, Venuto RC, Anti-CD20 sirolimus monotherapy, Pediatr Transplant, 2005;9:249–53.
23. Keogh KA, Wylam ME, Stone JH, Specks U, Induction of monoclonal antibody (Rituximab) for life-threatening hemolytic- 68. Ganne V, Siddiqi N, Kamaplath B, et al., Humanised antiCD20
remission by B lymphocyte depletion in eleven patients with uremic syndrome, Clin Transplant, 2005;19:423–6. monoclonal antibody (Rituximab) treatment for post-transplant
refractory antineutrophil cytoplasmic antibody-associated 47. Yomtovian R, Niklinski W, Silver B, et al., Rituximab for chronic lymphoproliferative disorder, Clin Transplant, 2003;17:417–22.
vasculitis, Arthritis Rheum, 2005;52:262–8. recurring thrombotic thrombocytopenic purpura: a case report 69. Gloor JM, Lager DJ, Fidler ME, et al., A Comparison of
24. Omdal R, Wildhagen K, Hansen T, et al., Anti-CD20 therapy of and review of the literature, Br J Haematol, 2004;124:787–95. Splenectomy versus Intensive Post-transplant Antidonor Blood
treatment-resistant Wegener’s granulomatosis: favourable but 48. Zheng X, Pallera AM, Goodnough LT, et al., Remission of Group Antibody Monitoring without Splenectomy in ABO-
temporary response, Scand J Rheumatol, 2005;34:229–32. chronic thrombotic thrombocytopenic purpura after treatment Incompatible Kidney Transplantation, Transplantation,
25. Smith KGC, Burns S, Jayne DRW, Effective Treatment of with cyclophosphamide and rituximab, Ann Intern Med, 2005;80:1572–7.
Refractory Vasculitis by B cell Depletion with Rituximab, Kidney 2003;138:105–8. 70. Sawada T, Fuchinoue S, Teraoka S, Successful A1-to-O ABO-
Blood Press R, 2004;28:170A. 49. Mandreoli M, Finelli C, Lopez A, et al., Successful resumption of incompatible kidney transplantation after a pre-conditioning
26. Specks U, Fervenza FC, McDonald TJ, Hogan MC, Response of epoetin alfa after rituximab treatment in a patient with pure red regimen consisting of antiCD20 monoclonal antibody infusions,
Wegener’s granulomatosis to anti-CD20 chimeric monoclonal cell aplasia, Am J Kidney Dis, 2004;44:757–61. splenectomy and double-filtration plasmapheresis,
antibody therapy, Arthritis Rheum, 2001;44:2836–40. 50. Gloor JM, DeGoey SR, Pineda AA, et al., Overcoming a positive Transplantation, 2002;74:1207–10.
27. Remuzzi G, Chiurchiu C, Abbate M, et al., Rituximab for crossmatch in living-donor kidney transplantation, Am J 71. Norden G, Brigg, D, Cockwell P, et al., ABO-incompatible live-
idiopathic membranous nephropathy, Lancet, Transplant, 20033:1017–23. donor renal transplantation using blood group A/B
2002;360:923–24. 51. Sawada T, Fuchinoue S, Kawase T, Kubota K, Teraoka S, carbohydrate antigen immunoadsorption and antiCD20
28. Ruggenent P, Chiurchiu C, Brusegan V, et al., Rituximab in Preconditioning regimen consisting of anti-CD20 monoclonal antibody treatment, Xenotransplantation, 2006;13:148–53.
idiopathic membranous nephropathy: a one-year prospective antibody infusions, splenectomy and DFPP-enabled non-
EUROPEAN RENAL DISEASE 2007 65
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76